Marc-Olivier Sirard, CPA, senior investment advisor at Fonds de solidarité FTQ, and Dr. Saumya Das, PhD, MD, Director of the Resynchronization and Advanced Cardiac Therapeutics Program at Massachusetts General Hospital, join our board of directors.

Dave Hutton is a school teacher by profession, and a Long QT Syndrome caregiver by devotion. Upon his daughter Isla’s diagnosis with Long QT Syndrome Type 3 in 2016, Dave left teaching to be the full-time caregiver to his little girl.

Alexander Thomas is a 17 year-old dance prodigy born in South Florida. Alexander also has Long QT Syndrome, a condition shared by his mother, Palmire, and his brother, Adrien. This is their journey, shared with the LQTS community.

Research collaboration with the Mayo Clinic in Rochester, Minnesota to evaluate novel pharmacologic treatments for LQTS, an arrhythmia associated with a prolonged QT interval that can cause sudden death.

Long QT Syndrome is a rare disorder that is often undiagnosed. LQTS causes an elongation between the Q and T waves during a heart beat. The lengthening of these waves can cause unexpected and life-threatening arrhythmias.

LQT Therapeutics raised up to C$1.8M seed funding led by Fonds de solidarité FTQ and other founding investors. Our aim is to develop a series of preclinical compounds as new treatment options for Long QT Syndrome and other arrhythmias.